Salubris Biotherapeutics, Inc. (SalubrisBio) is a clinical-stage biotechnology company focused on the discovery and development of novel antibody and protein-based therapeutics. The company targets significant medical needs in the areas of cardiovascular disease, oncology, and neurodegenerative diseases, which are among the leading causes of death globally. SalubrisBio operates in the biopharmaceutical market, serving patients with severe and life-threatening conditions. The business model revolves around the research, development, and clinical testing of innovative therapeutic molecules, aiming to bring these therapies to market through regulatory approval and commercialization. Revenue is generated through partnerships, licensing agreements, and eventual product sales once therapies receive market approval.

Keywords: biotechnology, antibody therapeutics, protein-based therapeutics, cardiovascular disease, oncology, neurodegenerative diseases, clinical-stage, novel therapies, biopharmaceutical, medical innovation.